ArticleBMC anesthesiology2025
Dexmedetomidine versus ketamine as adjuvants in external oblique intercostal plane block for post thoracotomy pain: a randomised trial.
Article in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06331182 (Comparison Between Role of Dexmedetomidine and Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison Between Role of Dexmedetomidine and Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain: A Randomized Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe external oblique intercostal plane block (EOIPB) is a novel block that targets explicitly the intercostal nerves to provide pain relief, reduce opioid use, and improve postoperative recovery. This study evaluated the effectiveness of dexmedetomidine (Dex) and Ketamine as adjuvants in EOIPB for post-thoracotomy pain (PTP).
methodsThis double-blind, randomised trial involved forty adults undergoing open thoracotomy. Cases were distributed equally into two groups. The Ketamine group received bupivacaine 0.25% with Ketamine, while the Dex group received bupivacaine 0.25% with dexmedetomidine.
resultsPatient-required intraoperative fentanyl consumption was not different between groups. Dex provided superior postoperative analgesia to Ketamine, with significantly lower pain scores at 8 h (median 2 vs. 3, p = 0.001) and 12 h (p = 0.035). Time to first rescue analgesia was prolonged (14.65 ± 2.25 vs. 10.26 ± 1.73 h, p < 0.001), and morphine consumption was notably reduced in the Dex group at both 24 h (5.4 ± 1.57 vs. 6.95 ± 1.43 mg, p = 0.003) and 48 h (7.95 ± 1.47 vs. 9.95 ± 1.43 mg, p < 0.001). The two groups did not exhibit any substantial variations in patient satisfaction and the incidences of bradycardia, hypotension, and postoperative nausea and vomiting.
conclusionsAs an adjuvant in EOIPB, Dex is superior to Ketamine. It provides a longer duration of analgesia, significantly reduces postoperative opioid consumption, and results in lower pain scores at specific time intervals, without a significant difference in adverse effects.
trial registrationRegistration at clinicaltrials.gov (NCT06331182) Date of registration: 2024-03-17.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.